Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The role of IMiDs alone or in combination in prostate cancer.

Nabhan C, Petrylak DP.

Clin Genitourin Cancer. 2012 Sep;10(3):141-6. doi: 10.1016/j.clgc.2012.03.005. Review.

PMID:
22608152
2.

Novel chemotherapies in development for management of castration-resistant prostate cancer.

Tewari AK, George DJ.

Curr Opin Urol. 2013 May;23(3):220-9. doi: 10.1097/MOU.0b013e32835f7da2. Review.

PMID:
23511791
3.

Novel approaches and future directions in castration-resistant prostate cancer.

Nabhan C, Parsons B, Touloukian EZ, Stadler WM.

Ann Oncol. 2011 Sep;22(9):1948-57. doi: 10.1093/annonc/mdq639.

PMID:
21252057
4.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Review.

PMID:
21592649
5.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
6.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.

Urology. 2003 Jul;62(1):99-104.

PMID:
12837431
7.

Docetaxel-based combination therapy for castration-resistant prostate cancer.

Galsky MD, Vogelzang NJ.

Ann Oncol. 2010 Nov;21(11):2135-44. doi: 10.1093/annonc/mdq050. Review.

PMID:
20351071
8.

New and emerging agents for the treatment of castration-resistant prostate cancer.

Higano CS, Crawford ED.

Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. doi: 10.1016/j.urolonc.2011.08.013. Review.

PMID:
22074657
9.

Drug resistance in metastatic castration-resistant prostate cancer.

Seruga B, Ocana A, Tannock IF.

Nat Rev Clin Oncol. 2011 Jan;8(1):12-23. doi: 10.1038/nrclinonc.2010.136. Review.

PMID:
20859283
10.

Castration-refractory prostate cancer: New drugs in the pipeline.

Schrijvers D, Van Erps P, Cortvriend J.

Adv Ther. 2010 May;27(5):285-96. doi: 10.1007/s12325-010-0038-1. Review.

PMID:
20532721
11.

[Study to castrate-resistant prostate cancer: AUO study AP 60/10].

Rexer H.

Urologe A. 2011 May;50(5):607-8. doi: 10.1007/s00120-011-2568-9. German. No abstract available.

PMID:
21523432
12.

Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.

Izumi K, Mizokami A, Shima T, Narimoto K, Sugimoto K, Kobori Y, Maeda Y, Konaka H, Koh E, Namiki M.

Anticancer Res. 2010 Jul;30(7):3077-81.

PMID:
20683058
13.

Total androgen blockade for metastatic cancer of the prostate.

BĂ©land G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM.

Am J Clin Oncol. 1988;11 Suppl 2:S187-90.

PMID:
3149456
14.

Satraplatin for the therapy of castration-resistant prostate cancer.

Sonpavde G, Sternberg CN.

Future Oncol. 2009 Sep;5(7):931-40. doi: 10.2217/fon.09.84. Review.

PMID:
19792961
16.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Review.

PMID:
15663992
17.

Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2012 Mar;8(1):31-42. doi: 10.1111/j.1743-7563.2011.01506.x. Review.

PMID:
22369442
18.

Castration refractory prostate cancer: cinderella finally comes to the ball.

Chowdhury S, Harper P, Powles T.

Onkologie. 2010;33(12):655-6. doi: 10.1159/000322635. No abstract available.

19.

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

Madan RA, Mohebtash M, Schlom J, Gulley JL.

Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi: 10.1517/14712590903321421.

PMID:
19857185
20.

Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.

Berry W, Eisenberger M.

Oncologist. 2005;10 Suppl 3:30-9. Review.

Supplemental Content

Support Center